Bone Biologics (BBLG) Retained Earnings (2010 - 2026)

Bone Biologics (BBLG) has reported Retained Earnings for 16 consecutive years, with -$88.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Retained Earnings fell 199.54% year-over-year to -$88.1 million; the TTM figure through Dec 2025 stood at -$88.1 million (down 199.54% YoY), while the FY2025 annual figure was -$88.1 million, down 199.54% from the prior year.
• Retained Earnings eased to -$88.1 million in Q4 2025 per BBLG's latest filing, from $93.5 million in the prior quarter.
• Across five years, Retained Earnings topped out at $93.5 million in Q3 2025 and bottomed at -$88.1 million in Q4 2025.
• Historically, Retained Earnings has averaged -$13.8 million across 5 years, with a median of -$70.1 million in 2021.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 232.08% — and 2025, when it soared 213.1%.
• Bone Biologics' Retained Earnings stood at -$70.5 million in 2021, then slipped by 2.11% to -$72.0 million in 2022, then declined by 12.44% to -$80.9 million in 2023, then soared by 209.39% to $88.5 million in 2024, then tumbled by 199.54% to -$88.1 million in 2025.
• Business Quant data shows BBLG's Retained Earnings at -$88.1 million in Q4 2025, $93.5 million in Q3 2025, and $93.4 million in Q2 2025.